Critical role of PI3K signaling for NF-κB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 1, 2011, Pages 272-277

  Kloo, Bernhard ^a   Nagel, Daniel ^a   Pfeifer, Matthias ^b   Grau, Michael ^c   Düwel, Michael ^a   Vincendeau, Michelle ^a   Dörken, Bernd ^b   Lenz, Peter ^c   Lenz, Georg ^b   Krappmann, Daniel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD79B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALT1 ENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL ACTIVATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIGENS, CD79; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 78651066552     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008969108     Document Type: Article

References (27)

1. Schulze-Luehrmann J, Ghosh S (2006) Antigen-receptor signaling to nuclear factor kappa B. Immunity 25:701-715.
2. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874.
3. Ngo VN, et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441:106-110.
4. Rosenwald A, et al.; Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346:1937-1947.
5. Coornaert B, et al. (2008) T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 9:263-271.
6. Düwel M, et al. (2009) A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 182:7718-7728.
7. Rebeaud F, et al. (2008) The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 9:272-281.
8. Ferch U, et al. (2009) Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 206:2313-2320.
9. Hailfinger S, et al. (2009) Essential role of MALT1 protease activity in activated B-cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 106:19946-19951.
10. Lenz G, et al. (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1679.
11. Davis RE, et al. (2010) Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92.
12. Hasselblom S, et al. (2010) High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 149:560-568.
13. Uddin S, et al. (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108:4178-4186.
14. Suzuki H, et al. (2003) PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction. Nat Immunol 4:280-286.
15. Deane JA, Fruman DA (2004) Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu Rev Immunol 22:563-598.
16. Hayakawa M, et al. (2006) Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 14:6847-6858.
17. Feldman RI, et al. (2005) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280:19867-19874.
18. Alessi DR, Cohen P (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55-62.
19. Lam LT, et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713.
20. Greten FR, Karin M (2004) The IKK/NF-kappaB activation pathway: A target for prevention and treatment of cancer. Cancer Lett 206:193-199.
21. Gauld SB, Cambier JC (2004) Src-family kinases in B-cell development and signaling. Oncogene 23:8001-8006.
22. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
23. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11:329-341.
24. Vasudevan KM, et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16:21-32.
25. Park SG, et al. (2009) The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells. Nat Immunol 10:158-166.
26. Srinivasan L, et al. (2009) PI3 kinase signals BCR-dependent mature B cell survival. Cell 139:573-586.
27. Nowak DE, Tian B, Brasier AR (2005) Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques 39:715-725.